Atrial fibrillation patients categorized as "Not for Anticoagulation" According to the 2014 Canadian cardiovascular society algorithm are not "Low Risk"

Canadian Journal of Cardiology

Volumn 31, Issue 1, 2015, Pages 24-28

  Lip, Gregory Y H ^a,b   Nielsen, Peter Brønnum ^a   Skjøth, Flemming ^a,c   Rasmussen, Lars Hvilsted ^a,c   Larsen, Torben Bjerregaard ^a,c  

^a AALBORG UNIVERSITY   (Denmark)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHADS2 SCORE; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG INDICATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; PRACTICE GUIDELINE; RISK ASSESSMENT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; CANADA; CLINICAL TRIAL; COMPLICATION; INCIDENCE; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; RISK FACTOR;

AGED; ALGORITHMS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CANADA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 84920395939     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.10.018     Document Type: Article

References (17)

1. Lip G.Y. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. Eur Heart J 2013, 34:1041-1049.
2. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012, 14:1385-1413.
3. National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation (clinical guideline 180). Available at: accessed December 2014. http://www.nice.org.uk/guidance/CG180.
4. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010, 137:263-272.
5. Verma A., Cairns J.A., Mitchell L.B., et al. 2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 2014, 30:1114-1130.
6. Lip GY, Nielsen PB, Skjoth F, etal. The value of the ESC guidelines for refining stroke risk stratification in patients with atrial fibrillation categorised as 'low risk' using the ATRIA stroke score: a nationwide cohort study [e-pub ahead of print]. Chest 2014;146:1337-46.
7. Friberg L., Rosenqvist M., Lip G.Y. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the swedish atrial fibrillation cohort study. Circulation 2012, 125:2298-2307.
8. Banerjee A., Lane D.A., Torp-Pedersen C., Lip G.Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012, 107:584-589.
9. Eckman M.H., Singer D.E., Rosand J., Greenberg S.M. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011, 4:14-21.
10. Apostolakis S., Lane D.A., Buller H., Lip G.Y. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemost 2013, 110:1074-1079.
11. Lip G.Y., Lane D.A. Modern management of atrial fibrillation requires initial identification of "low-risk" patients using the CHADS-VASc score, and not focusing on "high-risk" prediction. Circ J 2014, 78:1843-1845.
12. Anandasundaram B., Lane D.A., Apostolakis S., Lip G.Y. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. JThromb Haemost 2013, 11:975-978.
13. Lin L.Y., Lee C.H., Yu C.C., et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-a nationwide database analysis. Atherosclerosis 2011, 217:292-295.
14. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort Study. Eur Heart J 2012, 33:1500-1510.
15. Olesen J.B., Lip G.Y., Lane D.A., et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012, 125:826:e813-e823.
16. Wagstaff A.J., Overvad T.F., Lip G.Y., Lane D.A. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM 2014, 107:955-967. [e-pub ahead of print].
17. Friberg L., Benson L., Rosenqvist M., Lip G.Y. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 2012, 344:e3522.